[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE477339T1 - Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung - Google Patents

Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Info

Publication number
ATE477339T1
ATE477339T1 AT06742440T AT06742440T ATE477339T1 AT E477339 T1 ATE477339 T1 AT E477339T1 AT 06742440 T AT06742440 T AT 06742440T AT 06742440 T AT06742440 T AT 06742440T AT E477339 T1 ATE477339 T1 AT E477339T1
Authority
AT
Austria
Prior art keywords
compositions
markers
treatment
outcome
predicting
Prior art date
Application number
AT06742440T
Other languages
English (en)
Inventor
Kirsten Nielsen
Bent Eilertsen
Tim Poulsen
Henning Mouridsen
Original Assignee
Dako Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark As filed Critical Dako Denmark As
Application granted granted Critical
Publication of ATE477339T1 publication Critical patent/ATE477339T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
AT06742440T 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung ATE477339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68607005P 2005-05-31 2005-05-31
PCT/DK2006/000300 WO2006128463A2 (en) 2005-05-31 2006-05-30 Compositions and methods for predicting outcome of treatment

Publications (1)

Publication Number Publication Date
ATE477339T1 true ATE477339T1 (de) 2010-08-15

Family

ID=35809661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06742440T ATE477339T1 (de) 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Country Status (6)

Country Link
US (1) US8679746B2 (de)
EP (1) EP1885878B1 (de)
AT (1) ATE477339T1 (de)
DE (1) DE602006016106D1 (de)
ES (1) ES2350648T3 (de)
WO (1) WO2006128463A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318732A1 (en) * 2008-05-28 2011-12-29 Singer Robert H Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
US8583380B2 (en) * 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
AU2010253978B2 (en) * 2009-05-29 2014-12-11 Ventana Medical Systems, Inc. Methods of scoring gene copy number in a biological sample using in situ hybridization
NZ608313A (en) 2010-09-24 2013-12-20 Univ Leland Stanford Junior Direct capture, amplification and sequencing of target dna using immobilized primers
US9556473B2 (en) * 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
CN106338423B (zh) 2015-07-10 2020-07-14 三斯坎公司 组织学染色的空间复用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479446C (en) 2003-08-28 2013-05-07 F.Hoffmann-La Roche Ag Correlation of the ratio of tp and dpd mrna expression levels in colorectal cancer with disease-free survival in 5-fu treated patients

Also Published As

Publication number Publication date
WO2006128463A3 (en) 2007-02-15
US20090042187A1 (en) 2009-02-12
EP1885878A2 (de) 2008-02-13
US8679746B2 (en) 2014-03-25
EP1885878B1 (de) 2010-08-11
ES2350648T3 (es) 2011-01-25
WO2006128463A2 (en) 2006-12-07
DE602006016106D1 (de) 2010-09-23

Similar Documents

Publication Publication Date Title
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
EP2125855A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und anderen krankheiten
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
TN2010000060A1 (en) Proteasome inhibitors
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
ATE477339T1 (de) Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE529536T1 (de) Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen
ATE522625T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
EP1720410A4 (de) Zusammensetzungen und verfahren für die behandlung und klinische remission von schuppenflechte
EP1797430A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties